Showing posts with label Nicholas. Show all posts
Showing posts with label Nicholas. Show all posts

Friday, May 2, 2008

Researchers Find that a Small Molecule Can Activate an Important Cancer Suppressor Gene

By activating a cancer suppressor gene, a small molecule called nutlin-3a can block cancer cell division, according to researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. This activation of the p53 gene leads to cellular senescence. An opportunity for new genetic mutations occurs each time a cell divides, so limiting the number of cell divisions in a cancer cell inhibits tumor progression.

Activation of p53 can suppress tumor growth through more than one mechanism. It can interfere with the cell cycle, prompting a cell with unrepaired DNA damage to commit suicide through a complex signaling pathway called apoptosis. Alternatively, p53 may trigger cellular senescence in response to DNA damage or cellular stress.

The expression of p53 is regulated by Mdm2, a protein that is overexpressed in several human cancers. Nutlins are small-molecule inhibitors that prevent the p53 protein from forming a complex with Mdm2, resulting in activation of p53. Previous studies have shown that nutlin can induce apoptosis in human cancer cells.

Protein interactions play significant roles in various aspects of the structural and functional organization of the cell, and their elucidation sheds light on the molecular mechanisms of biological processes. Having a network of protein interactions will allow researchers to identify drugs that target pathways related to a specific disease while avoiding pathways associated with unwanted side effects and toxicity. Key to advancing our knowledge of biochemical pathways and networks is the intelligent analysis and mining of available literature, which is a vast resource of information on thousands of interactions.

NetPro™ is the largest database in the world (expertly curated) on protein-protein interactions. NetPro™ would be invaluable to any investigator in shortlist his genes of interest from a high-throughput experiment as it's interactive query interface (WebMINE) provides answers for questions like,
  • Is the protein a surface receptor?
  • Is it a major switch?
  • Is it Druggable?
  • What is the patent position on the same?
  • What is the nearest path between the 2 genes of my interest?
  • Is this protein known to be involved in a particular disease/pathway
Do you want to know more?

Thursday, April 17, 2008

Nicholas Piramal India Limited to Piramal Healthcare Limited

Nicholas Piramal India Limited ("NPIL", name proposed to be changed to Piramal Healthcare Limited) is one of India's largest pharmaceutical companies, with a growth track record of above 30% CAGR since 1988. NPIL had consolidated revenues of US$602 million in 2006-07. The Company is currently ranked 4th in the Indian market with a diverse product portfolio spanning nine therapeutic areas. The Company is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia. NPIL is listed in India on the National Stock Exchange (Ticker: NICOLASPIR) and the Bombay Stock Exchange (Ticker: 500302). The name change from Nicholas Piramal India Limited to Piramal Healthcare Limited is subject to approval by the Company's shareholders and Central Government.